



Contents lists available at ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

Brønsted acid promoted one-pot synthesis of 4-aryl-3,4-dihydrocoumarins

Cheng Chen^b, Rui Zhang^a, Long Lin^a, Guang-Fu Yang^{a,*}, Qiong-You Wu^{a,*}

^aKey Laboratory of Pesticide & Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, PR China

^bState Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Wuhan University of Technology, Wuhan 430070, PR China

ARTICLE INFO

Article history:

Received 21 March 2016

Received in revised form 4 May 2016

Accepted 5 May 2016

Available online xxx

Keywords:

Dihydrocoumarins

Friedel–Crafts alkylation

Cycloaddition

Brønsted acid

Perchloric acid

ABSTRACT

4-Aryl-3,4-dihydrocoumarins are a class of valuable molecules demonstrating attractive pharmaceutical and biological properties. In this paper, we designed a new and facile approach to synthesis of 4-aryl-3,4-dihydrocoumarin derivatives by Brønsted acid catalyzed Friedel–Crafts alkylation and cycloaddition reaction. With this protocol, 15 examples of 4-aryl-3,4-dihydrocoumarins were successfully prepared with yields ranging from 82 to 99%.

© 2016 Elsevier Ltd. All rights reserved.

1. Introduction

Coumarins have widely existed in a variety of natural products, pharmaceuticals, and agrochemicals, and they are attractive due to their *anti-inflammatory*, *anti-aging*, *anti-oxidative* and *anti-cancer* activities.¹ Besides, dihydrocoumarins have been frequently used as food flavouring² and fragrance in cosmetics,³ and they are also well-known in perfumery industries.⁴ Among this class of compounds, 4-aryl-3,4-dihydrocoumarins are particularly interesting since they exhibit promising activities such as *anti-herpetic*,⁵ *anti-bacterial*,^{6,7} *anti-viral*,⁸ *anti-hypertension*,⁹ *anti-inflammatory*,¹⁰ antioxidant activities,¹ as well as aldose reductase inhibition¹¹ and protein kinase inhibition.¹² For instance, the dihydrocoumarin **1** is a synthetic compound showing excellent *in vitro* *anti-bacterial* activity against members of the *Trypanosoma* family (Fig. 1).^{6,7} In addition, compound **2**, a natural dihydrocoumarin, demonstrates outstanding *anti-inflammatory* and antioxidant activities (Fig. 1).¹³

Owing to the diverse advantages of 4-aryl-3,4-dihydrocoumarins, it is of vital importance to develop efficient synthetic approaches for this kind of compounds. Conventional methods for their synthesis include the transition-metal-mediated

catalytic hydrogenation,^{14,15} treatment of cinnamic acid derivatives (cinnamic acids,^{16–24} cinnamoyl chlorides,²⁵ or cinnamate esters^{26,27}) with phenols, annulation reactions of phenols with other reagents,^{28–30} the use of oxidants on acids,^{31–35} arylacrylate lactonization,^{6,7,36} and one-pot synthesis via Fischer carbenes.³⁷




Fig. 1. Representative examples of synthetic and natural 4-aryl-3,4-dihydrocoumarins.


Although various methods have been developed, it is still highly desirable to design a facile and economic route for synthesis of 4-aryl dihydrocoumarins under mild reaction conditions. Through literature survey, we poured our attention to a report by Claude et al. describing an efficient intramolecular cycloaddition reaction from a secondary alcohol group and an ester moiety in the presence

* Corresponding authors. Tel.: +86 27 67867800; fax: +86 27 67867141; e-mail addresses: gfyang@mail.ccnu.edu.cn (G.-F. Yang), qywu@mail.ccnu.edu.cn (Q.-Y. Wu).


<http://dx.doi.org/10.1016/j.tet.2016.05.007>

0040-4020/© 2016 Elsevier Ltd. All rights reserved.


(a) Claude's work:



(b) Bra's and Barbero's works:




(c) This work:



2. Results and discussion

Table 1
Optimization of reaction conditions^a





Entry	Brønsted acid	Solvent	3a: 4a: Brønsted acid	Time (min)	Yield ^b
1	TfOH	DCM	1:2:2	930	90%
2	conc. HCl	DCM	1:2:2	1440	85%
3	TsOH	DCM	1:2:2	1440	85%
4	MsOH	DCM	1:2:2	30	88%
5	HClO ₄	DCM	1:2:2	20	90%
6	AcOH	DCM	1:2:2	1440	— ^c
7	HClO ₄	DCM	1:2:3	10	92%
8	HClO ₄	DCE	1:2:3	10	91%
9	HClO ₄	CHCl ₃	1:2:3	10	90%
10	HClO ₄	THF	1:2:3	10	50%
11	HClO ₄	Acetone	1:2:3	10	65%
12	HClO ₄	MeOH	1:2:3	10	55%
13	HClO ₄	Et ₂ O	1:2:3	10	90%
14	HClO ₄	MeCN	1:2:3	10	95%
15 ^d	HClO ₄	MeCN	1:2:3	10	99%

^d 3.0 mL acetonitrile was used.

With the optimized reaction conditions in hand, the substrate scope and limitations of this method were investigated. A range of 4-aryl dihydrocoumarins were obtained in excellent yields (Table 2). *tert*-Butyl 3-hydroxy-3-(2-hydroxyphenyl)propanoate

Table 2
Investigation of the substrate scope


^a Isolated yields.

(**3a**), with both R_1 and R_2 as H, reacted smoothly with various electron-rich arenes to give compounds **5a–5d** with the yields ranging from 84% to 99%. Heteroarenes such as 2-methylfuran and 2-methylthiophene can also tolerate this reaction and produced the respective products **5e** and **5f** in good yields. In addition, *tert*-butyl 3-hydroxy-3-(2-hydroxyphenyl)propanoate (**3b**) where a methyl group was assembled at the R_1 position was further utilized as the starting material. The results indicated that 1,3-dimethoxybenzene (**4a**), anisole (**4b**), 1,3-dimethoxy-2-methylbenzene (**4d**), 2-methylthiophene (**4f**) and 1-methyl-1H-indole (**4g**) could be successfully transformed into the corresponding dihydrocoumarins with a quaternary carbon atom at the benzylic position (**5g–5k**). It was worth noting that no noteworthy steric effect was observed in terms of the excellent yields obtained. Moreover, incorporation of a methyl group at the *p*-position of phenolic ring of compound **3** did not have significant influence on the product yields since compound **5l–5o** with the yields ranging from 84% to 93% were obtained depending on the aryl substituent introduced.

The plausible mechanism of the reaction was described in Scheme 1. It was assumed that compound **5a** could be obtained via two processes including a process featuring an S_N1 -type alcohol nucleophilic substitution via a benzylic carbenium species (also called Friedel–Crafts alkylation)^{39,40} and a cycloaddition process,³⁸ and the major difference of the two pathways lies in the sequence of the two processes. In pathway 1, treatment of **3a** with perchloric acid initially afforded a benzylic carbocation **I**, which then reacted with **4a** to give intermediate **II**. Afterwards, intermediate **II** could go through an intramolecular cycloaddition under an acidic condition to generate **5a** with elimination of *tert*-butanol. In pathway 2, Brønsted acid-aided intramolecular cycloaddition occurred first to produce intermediated **III**, which could be then transformed to the corresponding carbenium ion **IV** in the presence of perchloric acid. Finally, the final product **5a** could be yielded via reaction of intermediate **IV** and **4a**.

3. Conclusion

In summary, we have developed a simple, mild and efficient method for synthesis of 4-aryl-3,4-dihydrocoumarins. Screening of



Scheme 1. The plausible mechanism of the formation of **5**.


the reaction conditions implied that the economic perchloric acid was the optimal Brønsted acid. Under the optimized reaction conditions, a variety of 4-aryl-3,4-dihydrocoumarins were efficiently synthesized in good to excellent yields. Considering the reaction mechanism, we proposed that two processes, an S_N1 -type alcohol nucleophilic substitution (or Friedel–Crafts alkylation) and a cycloaddition reaction, could be realized in one pot with the aid of perchloric acid.

4. Experimental section

4.1. General considerations

^1H NMR spectra were recorded on a VARIAN Mercury-Plus 600 spectrometer in CDCl_3 with TMS as the internal reference, ^{13}C NMR spectra were recorded in CDCl_3 on a VARIAN Mercury-Plus 600 (151 MHz) spectrometer, and chemical shifts (δ) are given in ppm relative to the centre line of a triplet at 77.0 ppm of CDCl_3 . The following abbreviations are used to designate multiplicities: s=singlet, d=doublet, t=triplet, dd=doublet of doublets, brs=broad singlet, m=multiplet. MS spectra were determined using a Trace MS 2000 organic mass spectrometry, and the signals were given in m/z . HRMS was taken on an Agilent 6520 Accurate-Mass Q-TOF instrument. Melting points were taken on a Buchi B-545 melting point apparatus and are uncorrected. Ordinary reagents and solvents were commercially available and treated with standard methods before use. Besides, compounds **4** including 1,3-dimethoxybenzene (**4a**), anisole (**4b**), 1,2-dimethoxybenzene (**4c**), 1,3-dimethoxy-2-methylbenzene (**4d**), 2-methylfuran (**4e**), 2-methylthiophene (**4f**), 1-methyl-1H-indole (**4g**) were also purchased from commercial suppliers.

4.2. General procedure for synthesis of compounds **3a–3c** (Scheme 2)




Scheme 2. Synthesis of **3a–3c**.

To a solution of diisopropyl amine (55.0 mmol) in THF (60 mL) was added dropwisely *n*-butyl lithium solution (55.0 mmol) at -78°C under inert atmosphere, and the mixture was stirred for 20 min at the same temperature. Then *t*-butyl acetate (55.0 mmol) was added slowly to the above mixture, followed by dropwise addition of salicylaldehyde (22.0 mmol) after 1 h. Afterwards, the mixture was stirred for additional 1.5 h and 15% citric acid solution (60 mL) was added. The mixture was then extracted with EtOAc (3×60 mL), and the resulted organic layer was washed with water (2×50 mL), brine (50 mL), dried over Na_2SO_4 , concentrated, and purified by column chromatography to afford the pure product (**3a**).

Synthesis of **3b** and **3c** was similar with that of **3a**.

4.3. General procedure for synthesis of compounds **5a–5o** (Scheme 3)

To a solution of **3** (2.00 mmol) in acetonitrile (3 mL) was added dropwisely HClO_4 (6.00 mmol) at 0°C . Then **4** (4.00 mmol) was added and the reaction mixture was stirred at 0°C for 10 min.

Scheme 3. Synthesis of **5** from **3** and **4**.

Afterwards, the mixture was directly purified by column chromatography to afford the pure products (**5a–5o**).

4.4. Analytical data for compounds **3a–3c** and **5a–5o**

4.4.1. tert-Butyl 3-hydroxy-3-(2-hydroxyphenyl)propanoate (3a). White solid: mp 87.5–89.0 °C. Isolated yield: 89%. ¹H NMR (600 MHz, CDCl₃): δ 8.31 (s, 1H), 7.18 (dd, *J*=7.4, 7.2 Hz, 1H), 6.96 (d, *J*=7.8 Hz, 1H), 6.88 (d, *J*=8.4 Hz, 1H), 6.83 (dd, *J*=7.8, 7.7 Hz, 1H), 5.24 (d, *J*=10.2 Hz, 1H), 4.66 (s, 1H), 2.91–2.86 (m, 1H), 2.66–2.62 (m, 1H), 1.49 (s, 9H); ¹³C NMR (151 MHz, CDCl₃): 172.57, 155.71, 129.17, 126.60, 125.34, 119.81, 117.38, 82.25, 71.60, 41.75, 28.04; MS (EI): *m/z*=238.12 (M⁺). HRMS (ESI): *m/z* calcd for C₁₃H₁₈O₄Na [M+Na]⁺: 261.10973; Found 261.10626.

4.4.2. tert-Butyl 3-hydroxy-3-(2-hydroxyphenyl)butanoate (3b).⁴¹ Pale yellow oil. Isolated yield: 98%. ¹H NMR (600 MHz, CDCl₃): δ 9.35 (s, 1H), 7.15 (dd, *J*=7.4, 7.2 Hz, 1H), 6.98 (d, *J*=7.8 Hz, 1H), 6.87 (d, *J*=7.8 Hz, 1H), 6.79 (dd, *J*=7.4, 7.2 Hz, 1H), 5.72 (s, 1H), 3.07 (d, *J*=16.8 Hz, 1H), 2.65 (d, *J*=16.2 Hz, 1H), 1.61 (d, *J*=7.2 Hz, 3H), 1.42 (s, 9H); ¹³C NMR (151 MHz, CDCl₃): 172.72, 156.08, 129.06, 128.89, 124.80, 119.27, 117.81, 82.63, 76.19, 45.21, 28.51, 27.89; MS (EI): *m/z*=252.06 (M⁺).

4.4.3. tert-Butyl 3-hydroxy-3-(2-hydroxy-5-methylphenyl)butanoate (3c). Pale yellow oil. Isolated yield: 84%. ¹H NMR (600 MHz, CDCl₃): δ 9.12 (brs, 1H), 6.95 (d, *J*=6.6 Hz, 1H), 6.78–6.76 (m, 2H), 5.64 (brs, 1H), 3.06 (d, *J*=15.6 Hz, 1H), 2.64 (d, *J*=16.2 Hz, 1H), 2.24 (s, 3H), 1.60 (s, 3H), 1.42 (s, 9H); ¹³C NMR (151 MHz, CDCl₃): 172.82, 153.76, 129.52, 128.60, 128.16, 125.35, 117.60, 82.58, 76.17, 45.27, 28.54, 28.49, 27.96, 27.91, 20.63; MS (EI): *m/z*=266.25 (M⁺); HRMS (ESI): *m/z* calcd for C₁₅H₂₂O₄Na [M+Na]⁺: 289.14103; Found: 289.13871.

4.4.4. 4-(2,4-Dimethoxyphenyl)chroman-2-one (5a). White solid: mp 81.5–83.0 °C. Isolated yield: 99%. ¹H NMR (600 MHz, CDCl₃): δ 7.29–7.28 (m, 1H), 7.11 (d, *J*=7.8 Hz, 1H), 7.07 (dd, *J*=7.4, 7.2 Hz, 1H), 7.03 (d, *J*=6.6 Hz, 1H), 6.74 (d, *J*=8.4 Hz, 1H), 6.48 (s, 1H), 6.38 (d, *J*=7.8 Hz, 1H), 4.59 (t, *J*=6.6 Hz, 1H), 3.80 (s, 3H), 3.78 (s, 3H), 3.09–3.06 (m, 1H), 2.98–2.94 (m, 1H); ¹³C NMR (151 MHz, CDCl₃): 168.11, 160.25, 157.73, 151.95, 128.66, 128.31, 125.29, 124.39, 121.14, 116.81, 104.18, 98.83, 55.25, 55.09, 35.30, 34.92; MS (EI): *m/z*=284.12 (M⁺). HRMS (ESI): *m/z* calcd for C₁₇H₁₇O₄ [M+H]⁺: 285.11214; Found: 285.10972.

4.4.5. 4-(4-Methoxyphenyl)chroman-2-one (5b).²⁶ White solid: mp 130.6–132.1 °C. Isolated yield: 84%. ¹H NMR (600 MHz, CDCl₃): δ 7.31–7.28 (m, 1H), 7.12 (d, *J*=7.8 Hz, 1H), 7.10–7.07 (m, 3H), 6.98 (d, *J*=7.8 Hz, 1H), 6.88 (d, *J*=9.0 Hz, 2H), 4.30 (t, *J*=7.2 Hz, 1H), 3.80 (s, 3H), 3.07–2.97 (m, 2H); ¹³C NMR (151 MHz, CDCl₃): 167.77, 158.94, 151.62, 132.15, 128.68, 128.59, 128.25, 126.18, 124.60, 117.05, 114.43, 55.27, 39.84, 37.16; MS (EI): *m/z*=254.11 (M⁺).

4.4.6. 4-(3,4-Dimethoxyphenyl)chroman-2-one (5c).⁴² White solid: mp 108.7–110.0 °C. Isolated yield: 88%. ¹H NMR (600 MHz, CDCl₃): δ 7.30 (dd, *J*=7.8, 7.6 Hz, 1H), 7.13 (d, *J*=8.4 Hz, 1H), 7.09 (dd, *J*=8.0, 7.8 Hz, 1H), 7.00 (d, *J*=7.8 Hz, 1H), 6.83 (d, *J*=7.8 Hz, 1H), 6.69 (d, *J*=8.4 Hz, 1H), 6.67 (s, 1H), 4.29 (t, *J*=7.2 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.09–3.05 (m, 1H), 3.03–2.99 (m, 1H); ¹³C NMR (151 MHz,

CDCl₃): 167.62, 151.53, 149.30, 148.39, 132.58, 128.72, 128.27, 126.00, 124.63, 119.66, 117.05, 111.43, 110.52, 55.92, 55.71, 40.29, 37.19; MS (EI): *m/z*=284.22 (M⁺).

4.4.7. 4-(2,4-Dimethoxy-3-methylphenyl)chroman-2-one (5d). White solid: mp 92.5–94.0 °C. Isolated yield: 99%. ¹H NMR (600 MHz, CDCl₃): δ 7.28 (dd, *J*=7.8, 7.6 Hz, 1H), 7.13 (d, *J*=7.6 Hz, 1H), 7.06 (dd, *J*=7.4, 7.2 Hz, 1H), 6.96 (d, *J*=7.2 Hz, 1H), 6.74 (d, *J*=8.8 Hz, 1H), 6.59 (d, *J*=8.4 Hz, 1H), 4.65 (t, *J*=7.2 Hz, 1H), 3.80 (s, 3H), 3.70 (s, 3H), 3.01–3.00 (m, 2H), 2.19 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): 167.94, 158.23, 157.15, 151.89, 128.47, 128.28, 126.28, 125.38, 124.56, 124.38, 119.97, 116.98, 106.51, 61.20, 55.64, 36.49, 34.33, 9.50; MS (EI): *m/z*=298.24 (M⁺); HRMS (ESI): *m/z* calcd for C₁₈H₁₉O₄ [M+H]⁺: 299.12779; Found: 299.12787.

4.4.8. 4-(5-Methylfuran-2-yl)chroman-2-one (5e).⁴³ Pale yellow oil. Isolated yield: 82%. ¹H NMR (600 MHz, CDCl₃): δ 7.30 (dd, *J*=7.8, 7.6 Hz, 1H), 7.18–7.08 (m, 3H), 5.89–5.86 (m, 2H), 4.33 (t, *J*=6.0 Hz, 1H), 3.21–3.16 (m, 1H), 3.02–2.97 (m, 1H), 2.24 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): 167.41, 152.37, 151.37, 150.78, 128.94, 128.18, 124.57, 123.47, 117.19, 107.69, 106.17, 34.74, 34.03, 13.52; MS (EI): *m/z*=228.16 (M⁺).

4.4.9. 4-(5-Methylthiophen-2-yl)chroman-2-one (5f). Pale yellow oil. Isolated yield: 84%. ¹H NMR (600 MHz, CDCl₃): δ 7.31 (dd, *J*=7.4, 7.2 Hz, 1H), 7.18 (d, *J*=7.2 Hz, 1H), 7.14–7.10 (m, 2H), 6.57 (s, 2H), 4.51 (t, *J*=6.0 Hz, 1H), 3.09 (d, *J*=6.0 Hz, 2H), 2.42 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): 167.14, 151.22, 140.96, 139.76, 129.02, 128.02, 125.57, 125.11, 125.02, 124.66, 117.23, 37.34, 36.36, 15.29; MS (EI): *m/z*=244.08 (M⁺); HRMS (ESI): *m/z* calcd for C₁₄H₁₂O₂Sn [M+Na]⁺: 267.04502; Found: 267.04555.

4.4.10. 4-(2,4-Dimethoxyphenyl)-4-methylchroman-2-one (5g). White solid: mp 110.4–111.8 °C. Isolated yield: 90%. ¹H NMR (600 MHz, CDCl₃): δ 7.24 (d, *J*=7.2 Hz, 1H), 7.08–7.05 (m, 2H), 7.01 (d, *J*=7.2 Hz, 1H), 6.90 (d, *J*=8.4 Hz, 1H), 6.46 (s, 1H), 6.40 (d, *J*=8.4 Hz, 1H), 3.80–3.79 (m, 4H), 3.63 (s, 3H), 2.59 (d, *J*=15.6 Hz, 1H), 1.73 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): 168.62, 160.34, 158.38, 150.60, 131.29, 128.37, 127.91, 126.07, 124.26, 123.87, 116.92, 103.77, 99.95, 55.23, 54.97, 40.84, 39.92, 26.56; MS (EI): *m/z*=298.15 (M⁺); HRMS (ESI): *m/z* calcd for C₁₈H₁₉O₄ [M+H]⁺: 299.12779; Found: 299.12839.

4.4.11. 4-(4-Methoxyphenyl)-4-methylchroman-2-one (5h). Pale yellow oil. Isolated yield: 89%. ¹H NMR (600 MHz, CDCl₃): δ 7.31 (dd, *J*=8.0, 7.8 Hz, 1H), 7.22 (d, *J*=7.8 Hz, 1H), 7.17 (dd, *J*=8.0, 7.8 Hz, 1H), 7.11–7.08 (m, 3H), 6.82 (d, *J*=9.0 Hz, 2H), 3.77 (s, 3H), 3.24 (d, *J*=15.6 Hz, 1H), 2.81 (d, *J*=15.6 Hz, 1H), 1.72 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): 167.57, 158.44, 151.08, 135.84, 131.03, 128.60, 127.25, 126.50, 124.63, 117.23, 113.95, 55.15, 43.81, 40.47, 27.57; MS (EI): *m/z*=268.13 (M⁺); HRMS (ESI): *m/z* calcd for C₁₇H₁₇O₃ [M+H]⁺: 269.11722; Found: 269.11735.

4.4.12. 4-(2,4-Dimethoxy-3-methylphenyl)-4-methylchroman-2-one (5i). White solid: mp 96.2–97.7 °C. Isolated yield: 92%. ¹H NMR (600 MHz, CDCl₃): δ 7.24 (d, *J*=7.2 Hz, 1H), 7.10 (d, *J*=7.8 Hz, 1H), 7.06 (dd, *J*=8.0, 7.8 Hz, 1H), 6.99–6.94 (m, 2H), 6.57 (d, *J*=8.4 Hz, 1H), 3.92 (d, *J*=16.2 Hz, 1H), 3.82 (s, 3H), 3.20 (s, 3H), 2.63 (d, *J*=16.2 Hz, 1H), 2.11 (s, 3H), 1.69 (s, 3H); ¹³C NMR (151 MHz, CDCl₃): 168.26, 158.59, 158.08, 150.40, 131.93, 128.37, 127.96, 126.61, 124.82, 124.16, 120.26, 116.92, 104.61, 60.00, 55.35, 41.46, 40.10, 27.79, 10.21; MS (EI): *m/z*=312.17 (M⁺); HRMS (ESI): *m/z* calcd for C₁₉H₂₁O₄ [M+H]⁺: 313.14344; Found: 313.14076.

4.4.13. 4-Methyl-4-(5-methylthiophen-2-yl)chroman-2-one (5j). Pink oil. Isolated yield: 95%. ¹H NMR (600 MHz, CDCl₃): δ 7.32

(dd, $J=8.0$, 7.8 Hz, 1H), 7.28 (d, $J=7.8$ Hz, 1H), 7.17 (dd, $J=8.0$, 7.8 Hz, 1H), 7.10 (d, $J=8.4$ Hz, 1H), 6.54–6.53 (m, 2H), 3.20 (d, $J=15.6$ Hz, 1H), 2.91 (d, $J=15.6$ Hz, 1H), 2.41 (s, 3H), 1.78 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3): 167.01, 150.61, 146.47, 139.45, 130.34, 128.93, 125.87, 124.74, 124.69, 124.28, 117.19, 44.59, 39.50, 28.28, 15.21; MS (EI): $m/z=258.08$ (M^+); HRMS (ESI): m/z calcd for $\text{C}_{15}\text{H}_{15}\text{O}_2\text{S}$ [$\text{M}+\text{H}$] $^+$: 259.07873; Found: 259.07875.

4.4.14. 4-Methyl-4-(1-methyl-1H-indol-3-yl)chroman-2-one (5k). Pale yellow oil. Isolated yield: 92%. ^1H NMR (600 MHz, CDCl_3): δ 7.34–7.29 (m, 2H), 7.23–6.98 (m, 6H), 6.83 (s, 1H), 3.77 (s, 3H), 3.54 (d, $J=15.6$ Hz, 1H), 2.78 (d, $J=16.2$ Hz, 1H), 1.82 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3): 168.13, 150.80, 137.92, 130.44, 128.39, 127.09, 126.92, 125.02, 124.54, 121.64, 120.48, 118.95, 117.47, 117.01, 109.69, 43.01, 37.31, 32.66, 26.78; MS (EI): $m/z=291.14$ (M^+); HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{18}\text{NO}_2$ [$\text{M}+\text{H}$] $^+$: 292.13321; Found: 292.13266.

4.4.15. 4-(2,4-Dimethoxyphenyl)-4,6-dimethylchroman-2-one (5l). White solid: mp 137.4–138.7 °C. Isolated yield: 93%. ^1H NMR (600 MHz, CDCl_3): δ 7.05 (d, $J=8.4$ Hz, 1H), 6.96 (d, $J=8.4$ Hz, 1H), 6.86 (d, $J=8.4$ Hz, 1H), 6.82 (s, 1H), 6.46 (s, 1H), 6.39 (d, $J=9.0$ Hz, 1H), 3.80–3.76 (m, 4H), 3.66 (s, 3H), 2.57 (d, $J=16.2$ Hz, 1H), 2.27 (s, 3H), 1.73 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3): 168.63, 160.17, 158.33, 148.52, 133.66, 130.78, 128.37, 128.31, 126.32, 123.90, 116.52, 103.66, 99.86, 55.09, 54.89, 40.80, 39.81, 26.35, 20.74; MS (EI): $m/z=312.16$ (M^+); HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{21}\text{O}_4$ [$\text{M}+\text{H}$] $^+$: 313.14344; Found: 313.14060.

4.4.16. 4-(4-Methoxyphenyl)-4,6-dimethylchroman-2-one (5m). Pale yellow oil. Isolated yield: 86%. ^1H NMR (600 MHz, CDCl_3): δ 7.11–7.08 (m, 3H), 7.00–6.98 (m, 2H), 6.82 (d, $J=9.0$ Hz, 2H), 3.78 (s, 3H), 3.21 (d, $J=15.6$ Hz, 1H), 2.78 (d, $J=16.2$ Hz, 1H), 2.33 (s, 3H), 1.70 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3): 167.81, 158.38, 149.02, 135.96, 134.22, 130.62, 129.06, 127.27, 126.81, 116.94, 113.91, 55.16, 43.97, 40.41, 27.59, 20.93; MS (EI): $m/z=282.14$ (M^+); HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{19}\text{O}_3$ [$\text{M}+\text{H}$] $^+$: 283.13287; Found: 283.13276.

4.4.17. 4-(2,4-Dimethoxy-3-methylphenyl)-4,6-dimethylchroman-2-one (5n). White solid: mp 117.4–118.7 °C. Isolated yield: 84%. ^1H NMR (600 MHz, CDCl_3): δ 7.03 (d, $J=8.4$ Hz, 1H), 6.99 (d, $J=8.4$ Hz, 1H), 6.95 (d, $J=8.4$ Hz, 1H), 6.75 (s, 1H), 6.57 (d, $J=8.4$ Hz, 1H), 3.87 (d, $J=15.6$ Hz, 1H), 3.83 (s, 3H), 3.21 (s, 3H), 2.59 (d, $J=15.6$ Hz, 1H), 2.24 (s, 3H), 2.11 (s, 3H), 1.68 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3): 168.45, 158.51, 158.07, 148.32, 133.59, 131.52, 128.45, 128.37, 126.87, 124.80, 120.20, 116.63, 104.58, 59.94, 55.29, 41.54, 40.04, 27.70, 20.60, 10.16; MS (EI): $m/z=326.17$ (M^+); HRMS (ESI): m/z calcd for $\text{C}_{20}\text{H}_{22}\text{O}_4\text{K}$ [$\text{M}+\text{K}$] $^+$: 365.11497; Found: 365.11168.

4.4.18. 4,6-Dimethyl-4-(5-methylthiophen-2-yl)chroman-2-one (5o). Pale yellow oil. Isolated yield: 85%. ^1H NMR (600 MHz, CDCl_3): δ 7.10 (d, $J=8.4$ Hz, 1H), 7.06 (s, 1H), 6.98 (d, $J=8.4$ Hz, 1H), 6.53–6.52 (m, 2H), 3.16 (d, $J=15.6$ Hz, 1H), 2.86 (d, $J=15.6$ Hz, 1H), 2.41 (s, 3H), 2.33 (s, 3H), 1.59 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3): 167.11, 148.56, 146.61, 139.30, 134.30, 129.92, 129.43, 126.17, 124.72, 124.25, 116.94, 44.74, 39.43, 28.29, 20.90, 15.17; MS (EI): $m/z=272.18$ (M^+); HRMS

(ESI): m/z calcd for $\text{C}_{16}\text{H}_{17}\text{O}_2\text{S}$ [$\text{M}+\text{H}$] $^+$: 273.09438; Found: 273.09420.

Acknowledgements

This research was supported by the National Natural Science Foundation of China (Nos. 21272091, 21472063 and 21502062).

Supplementary data

Supplementary data associated with this article can be found in the online version, at <http://dx.doi.org/10.1016/j.tet.2016.05.007>.

References and notes

- Zhang, X. F.; Wang, H. M.; Song, Y. L.; Nie, L. H.; Wang, L. F.; Liu, B.; Shen, P. P.; Liu, Y. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 949.
- Jenner, P. M.; Hagan, E. C.; Taylor, J. M.; Cook, E. L.; Fitzhugh, O. G. *Food Cosm. Toxicol.* **1964**, *2*, 327.
- Rastogi, S. C.; Johansen, J. D.; Menne, T. *Contact Dermat.* **1996**, *34*, 423.
- Mazurella, J.; Bramnick, E. *Soap Perfum. Cosmet.* **1961**, *34*, 743.
- Takechi, M.; Tanaka, Y.; Takehara, M.; Nonaka, G.-I.; Nishioka, I. *Phytochemistry* **1985**, *24*, 2245.
- Speranza, G.; DiMeo, A.; Zanzola, S.; Fontana, G.; Manitto, P. *Synthesis* **1997**, 931.
- Bezerra, M. Z. B.; Machado, M. I. L.; Morais, S. M.; Braz-Filho, R. *J. Braz. Chem. Soc.* **1997**, *8*, 229.
- Weaver, J. L.; Pine, P. S.; Dutschman, G.; Cheng, Y.-C.; Lee, K.-H.; Aszalos, A. *Biochem. Pharmacol.* **1992**, *43*, 2479.
- Lin, T.-C.; Hsu, F.-L.; Cheng, J.-T. *J. Nat. Prod.* **1993**, *56*, 629.
- Yao, C.-S.; Lin, M.; Wang, L. *Chem. Pharm. Bull.* **2006**, *54*, 1053.
- Iinuma, M.; Tanaka, T.; Mizuno, M.; Katsuzaki, T.; Ogawa, H. *Chem. Pharm. Bull.* **1989**, *37*, 1813.
- Hsu, F. L.; Nonaka, G. I.; Nishioka, I. *Chem. Pharm. Bull.* **1985**, *33*, 3142.
- Santos, W. H. D.; Silva-Filho, L. C. D. *Synthesis* **2012**, *44*, 3361.
- McGuire, M. A.; Shilcrat, S. C.; Sorenson, E. *Tetrahedron Lett.* **1999**, *40*, 3293.
- Park, J. O.; Youn, S. W. *Org. Lett.* **2010**, *12*, 2258.
- Singh, J.; Kaur, J.; Nayyar, S.; Kad, G. L. *J. Chem. Res. (S)* **1998**, 280.
- Shukla, M. R.; Patil, P. N.; Wadgaonkar, P. P.; Josh, P. N.; Salunkhe, M. M. *Synth. Commun.* **2000**, *30*, 39.
- Jia, C.; Kitamura, T.; Fujiwara, Y. *Acc. Chem. Res.* **2001**, *34*, 633.
- Ritleng, V.; Sirlin, C.; Pfeffer, M. *Chem. Rev.* **2002**, *102*, 1731.
- Li, K.; Foresee, L. N.; Tunge, J. A. *J. Org. Chem.* **2005**, *70*, 2881.
- Roelens, F.; Huvaere, K.; Dhooge, W.; Van Cleemput, M.; Comhaire, F.; De Keukeleire, D. *Eur. J. Med. Chem.* **2005**, *40*, 1042.
- Jagdale, A. R.; Sudalai, A. *Tetrahedron Lett.* **2007**, *48*, 4895.
- Escobar, A. M.; Ruiz, D. M.; Autino, J. C.; Romanelli, G. P. *Res. Chem. Intermed.* **2015**, *41*, 10109.
- Kamat, D. P.; Tilve, S. G.; Kamat, V. P. *Tetrahedron Lett.* **2012**, *53*, 4469.
- Zhang, Z.; Ma, Y.; Zhao, Y. *Synlett* **2008**, 1091.
- Aoki, S.; Amamoto, C.; Oyama, J.; Kitamura, T. *Tetrahedron* **2005**, *61*, 9291.
- Niharika, P.; Ramulu, B. V.; Satyanarayana, G. *Org. Biomol. Chem.* **2014**, *12*, 4347.
- Fillion, E.; Dumas, A. M.; Kuropatwa, B. A.; Malhotra, N. R.; Sitler, T. C. *J. Org. Chem.* **2006**, *71*, 409.
- Rodrigues-Santos, C. E.; Echevarria, A. *Tetrahedron Lett.* **2007**, *48*, 4505.
- Duan, S.; Jana, R.; Tunge, J. A. *J. Org. Chem.* **2009**, *74*, 4612.
- Gu, Y.; Xue, K. *Tetrahedron Lett.* **2010**, *51*, 192.
- Kumar, A.; Kumar, P.; Tripathi, V. D.; Srivastava, S. *RSC Adv.* **2012**, *2*, 11641.
- Laufer, M. C.; Hausmann, H.; Hölderich, W. F. *J. Catal.* **2003**, *218*, 315.
- Tang, E.; Li, W.; Gao, Z. Y.; Gu, X. *Chin. Chem. Lett.* **2012**, *23*, 631.
- Reddy, C. R.; Srikanth, B.; Narsimha Rao, N.; Shin, D.-S. *Tetrahedron* **2008**, *64*, 11666.
- Youn, S. W.; Pastine, S. J.; Sames, D. *Org. Lett.* **2004**, *6*, 581.
- Barluenga, J.; Andina, F.; Aznar, F. *Org. Lett.* **2006**, *8*, 2703.
- Spino, C.; Mayes, N.; Desfossés, H.; Sotheeswaran, S. *Tetrahedron Lett.* **1996**, *37*, 6503.
- Le Bras, J.; Muzart, J. *Tetrahedron* **2007**, *63*, 7942.
- Barbero, M.; Cadamuro, S.; Dughera, S.; Rucci, M.; Spano, G.; Venturello, P. *Tetrahedron* **2014**, *70*, 1818.
- Carganico, G.; Cozzi, P.; Orsini, G. *J. Med. Chem.* **1983**, *26*, 1767.
- Lee, J. M.; Tseng, T. H.; Lee, Y. J. *Synthesis* **2001**, 2247.
- Yu, X. Q.; Shirai, T.; Yamamoto, Y.; Miyaura, N. *Chem.—Asian J.* **2011**, *6*, 932.